Among active 13F managers last quarter, 11 opened and 27 added, while 10 reduced; the largest holder to move was Frazier Life Sciences Management, L.P. (+491%). Over the last 180 days, 4 insiders sold and none bought, a net -$222K in open-market trades.
38 adding vs 10 trimming; insiders net sold $222K.
198 tracked 13F filers disclose a position in ALLO as of the latest SEC 13F filings, a combined $525.7M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 22.4M | $46.7M | ▲+491% Added · +18.6M sh | Q2 2026 | |
| 2 | Pfizer Inc | 22.0M | $46.9M | —Held | Q2 2026 | |
| 3 | BlackRock, Inc. | 19.1M | $46.6M | ▲+8.0% Added · +1.4M sh | Q1 2026 | |
| 4 | State Street Corp | 19.0M | $39.6M | ▲+120% Added · +10.4M sh | Q2 2026 | |
| 5 | TPG GP A, LLC | 18.7M | $45.7M | —Held | Q1 2026 | |
| 6 | Citadel Advisors LLC | 10.1M | $21.0M | ▲+48% Added · +3.3M sh | Q2 2026 | |
| 7 | Primecap Management Co | 8.4M | $20.4M | ▲+2.9% Added · +240K sh | Q1 2026 | |
| 8 | Geode Capital Management, LLC | 7.0M | $14.7M | ▲+71% Added · +2.9M sh | Q2 2026 | |
| 9 | Vanguard Capital Management LLC | 6.9M | $16.9M | →New filer Inherited book · not a new buyer | Q1 2026 | |
| 10 | Price T Rowe Associates Inc | 5.4M | $13.1M | ▲+68% Added · +2.2M sh | Q1 2026 | |
| 11 | Two Sigma Investments, LP | 5.4M | $13.1M | ▲+57% Added · +2.0M sh | Q1 2026 | |
| 12 | Patient Square Capital LP | 5.0M | $10.5M | ▲+46% Added · +1.6M sh | Q2 2026 | |
| 13 | Candriam S.C.A. | 4.3M | $9.0M | ▲+45% Added · +1.3M sh | Q2 2026 | |
| 14 | Woodline Partners LP | 3.5M | $8.5M | ▲~0% Added · +579 sh | Q1 2026 | |
| 15 | Marshall Wace, LLP | 3.4M | $8.4M | ▲12× Added · +3.2M sh | Q1 2026 | |
| 16 | Millennium Management LLC | 3.3M | $8.1M | ▲+80% Added · +1.5M sh | Q1 2026 | |
| 17 | Walleye Capital LLC | 3.3M | $6.8M | ▲New +3.3M sh | Q2 2026 | |
| 18 | RTW Investments, LP | 3.3M | $6.8M | ▲New +3.3M sh | Q2 2026 | |
| 19 | Ghisallo Capital Management LLC | 3.0M | $6.2M | ▲New +3.0M sh | Q2 2026 | |
| 20 | Wildcat Capital Management, LLC | 2.9M | $6.1M | —Held | Q2 2026 | |
| 21 | Goldman Sachs Group Inc | 2.8M | $6.7M | ▲+21% Added · +477K sh | Q1 2026 | |
| 22 | D. E. Shaw & Co., Inc. | 2.8M | $6.7M | ▲+115% Added · +1.5M sh | Q1 2026 | |
| 23 | Boxer Capital Management, LLC | 2.7M | $6.6M | ▲New +2.7M sh | Q1 2026 | |
| 24 | AQR Capital Management LLC | 2.5M | $6.1M | ▲+74% Added · +1.1M sh | Q1 2026 | |
| 25 | Nuveen, LLC | 2.3M | $5.6M | ▲+751% Added · +2.0M sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 11 funds opened a new position in ALLO and 27 added to an existing one, while 10 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 21, 2026 | Douglas Earl Martin | SVP, General Counsel | Sell (S) | 30K | $63K |
| Apr 21, 2026 | Yoshiyama Annie | SVP, Finance | Sell (S) | 10K | $22K |
| Mar 31, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell (S) | 3K | $7K |
| Mar 16, 2026 | Chang David D | President and CEO, Director | Sell (S) | 48K | $118K |
| Mar 16, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell (S) | 5K | $12K |
| Mar 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell (S) | 7K | $19K |
| Feb 2, 2026 | Douglas Earl Martin | SVP, General Counsel | Sell (S) | 23K | $40K |
| Feb 2, 2026 | Roberts Zachary | EVP of R&D | Sell (S) | 36K | $63K |
| Feb 2, 2026 | Yoshiyama Annie | SVP, Finance | Sell (S) | 4K | $7K |
| Feb 2, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell (S) | 24K | $42K |
| Feb 2, 2026 | Chang David D | President and CEO, Director | Sell (S) | 95K | $171K |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell (S) | 8K | $13K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Latest quarterly filings | 55 | 21 | – |
Insiders Form 4 open-market | 0 | 4 | -$222K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital DISCLOSED rotating, as of the latest public SEC 13F filings. It is DATA, NOT investment advice, a recommendation, or a prediction. Filings lag ~45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
No filings captured for this ticker in the live stream yet.
Connected entities for ALLO
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ALLO/capital-change-brief"
Use Arkolith's capital_change_brief for ALLO. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for ALLO. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.